^
+ Follow DR. MAQBOOL JAFARY Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 237722
                    [Title] => Results of landmark heart study bared
                    [Summary] => More than 2,000 heart specialists and other practicing physicians gathered at the Le Pavillion in Manila last Jan. 22 to listen to the presentation of the results and clinical implications of a landmark study that researchers hope will change the medical landscape in the management of heart diseases.


Results of VALIANT (Valsartan in Acute Myocardial Infarction Trial) was presented to doctors from all over the country by Prof. Inder Anand, chief of the Cardiology Section of the Veterans Affair Medical Center in Minneapolis, USA.
[DatePublished] => 2004-02-05 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 236012 [Title] => Landmark trial shows benefits of ‘valsartan’ [Summary] => Internationally respected medical authorities reported at the American Heart Association meeting held recently in Orlando, Florida that valsartan, a drug for high blood pressure belonging to the angiotensin II receptor blocker (ARB) family, is as effective as the ACE-inhibitor captopril in reducing the risk of death and other non-fatal cardiovascular events (CV) among high-risk patients, as results of the VALIANT study show.
[DatePublished] => 2004-01-22 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
DR. MAQBOOL JAFARY
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 237722
                    [Title] => Results of landmark heart study bared
                    [Summary] => More than 2,000 heart specialists and other practicing physicians gathered at the Le Pavillion in Manila last Jan. 22 to listen to the presentation of the results and clinical implications of a landmark study that researchers hope will change the medical landscape in the management of heart diseases.


Results of VALIANT (Valsartan in Acute Myocardial Infarction Trial) was presented to doctors from all over the country by Prof. Inder Anand, chief of the Cardiology Section of the Veterans Affair Medical Center in Minneapolis, USA.
[DatePublished] => 2004-02-05 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 236012 [Title] => Landmark trial shows benefits of ‘valsartan’ [Summary] => Internationally respected medical authorities reported at the American Heart Association meeting held recently in Orlando, Florida that valsartan, a drug for high blood pressure belonging to the angiotensin II receptor blocker (ARB) family, is as effective as the ACE-inhibitor captopril in reducing the risk of death and other non-fatal cardiovascular events (CV) among high-risk patients, as results of the VALIANT study show.
[DatePublished] => 2004-01-22 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with